Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Cash from Operations (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Cash from Operations for 11 consecutive years, with 417347000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 455.28% to 417347000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1127580000.0 through Dec 2025, up 901.8% year-over-year, with the annual reading at 1127580000.0 for FY2025, 901.8% up from the prior year.
  • Cash from Operations for Q4 2025 was 417347000.0 at BeOne Medicines, up from 402553000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 417347000.0 in Q4 2025, with the low at 563777000.0 in Q1 2023.
  • Average Cash from Operations over 5 years is 116545750.0, with a median of 158613000.0 recorded in 2023.
  • The sharpest move saw Cash from Operations plummeted 350.36% in 2022, then skyrocketed 455.28% in 2025.
  • Over 5 years, Cash from Operations stood at 127092000.0 in 2021, then crashed by 350.36% to 318191000.0 in 2022, then skyrocketed by 30.34% to 221638000.0 in 2023, then skyrocketed by 133.91% to 75160000.0 in 2024, then surged by 455.28% to 417347000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 417347000.0, 402553000.0, and 263598000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.